Keith Tapper
Stock Analyst at BMO Capital
(0.09)
# 4,129
Out of 4,829 analysts
6
Total ratings
16.67%
Success rate
-23.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Keith Tapper
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NGNE Neurogene | Maintains: Outperform | $45 → $16 | $17.21 | -7.03% | 4 | Apr 14, 2025 | |
| TSHA Taysha Gene Therapies | Initiates: Outperform | $5 | $2.25 | +122.22% | 1 | Jun 27, 2024 | |
| ACAD ACADIA Pharmaceuticals | Initiates: Outperform | $31 | $17.34 | +78.78% | 1 | Jun 27, 2024 |
Neurogene
Apr 14, 2025
Maintains: Outperform
Price Target: $45 → $16
Current: $17.21
Upside: -7.03%
Taysha Gene Therapies
Jun 27, 2024
Initiates: Outperform
Price Target: $5
Current: $2.25
Upside: +122.22%
ACADIA Pharmaceuticals
Jun 27, 2024
Initiates: Outperform
Price Target: $31
Current: $17.34
Upside: +78.78%